Actin filament-associated protein 1 (AFAP1) is an adaptor protein of cSrc that binds to filamentous actin and regulates the activity of this tyrosine kinase to affect changes to the organization of the actin cytoskeleton. In breast and prostate cancer cells, AFAP1 has been shown to regulate cellular responses requiring actin cytoskeletal changes such as adhesion, invadopodia formation and invasion. However, a normal physiologic role for AFAP1 has remained elusive. In this study, we generated an AFAP1 knockout mouse model that establishes a novel physiologic role for AFAP1 in lactation. Specifically, these animals displayed a defect in lactation that resulted in an inability to nurse efficiently. Histologically, the mammary glands of the lactating knockout mice were distinguished by the accumulation of large cytoplasmic lipid droplets in the alveolar epithelial cells. There was a reduction in lipid synthesis and the expression of lipogenic genes without a corresponding reduction in the production of β-casein, a milk protein. Furthermore, these defects were associated with histologic and biochemical signs of precocious involution. This study also demonstrated that AFAP1 responds to prolactin, a lactogenic hormone, by forming a complex with cSrc and becoming tyrosine phosphorylated. Taken together, these observations pointed to a defect in secretory activation. Certain characteristics of this phenotype mirrored the defect in secretory activation in the cSrc knockout mouse, but most importantly, the activity of cSrc in the mammary gland was reduced during early lactation in the AFAP1-null mouse and the localization of active cSrc at the apical surface of luminal epithelial cells during lactation was selectively lost in the absence of AFAP1. These data define, for the first time, the requirement of AFAP1 for the spatial and temporal regulation of cSrc activity in the normal breast, specifically for milk production.
INTRODUCTION
The known role of the cSrc tyrosine kinase in various cellular functions and cancer progression necessitates a deeper understanding of the adaptor proteins that regulate the spatial and temporal activity of cSrc. 1 One such adapter protein, originally identified as a substrate and binding partner of oncogenic variants of cSrc, is the actin filament-associated protein 1 (AFAP1, formerly AFAP-110). 2 AFAP1 is the prototypical member of a family of three structurally related proteins: AFAP1, AFAP1 like-1 and AFAP1 like-2 (alternatively XB-130). The structure of AFAP1 includes two pleckstrin homology domains, one of which harbors a binding site for protein kinase C, 3 SH2 and SH3 binding motifs for cSrc 4, 5 and carboxy-terminal domains that mediate self-association and interactions with f-actin. 6 AFAP1 is a substrate of protein kinase Cα as well as the Src family kinases, cSrc and Fyn. 2, 4, 7 One proposed function for AFAP1 is that it acts as an adaptor protein that localizes kinases involved in the organization of the actin cytoskeleton. [7] [8] [9] [10] In addition, AFAP1 can crosslink actin filaments, thereby affecting the integrity of the actin cytoskeleton. 3, 6, [11] [12] [13] The function of AFAP1 in oncogenesis has been examined in both breast and prostate cancer. The loss of AFAP1 in prostate cancer cells reduced the rate of proliferation and orthotopic tumor formation in nude mice. 14 The loss of AFAP1 also reduced focal complex/adhesion formation and cellular adhesion to extracellular matrix proteins in both breast and prostate cancer cells. 10, 14 Silencing of AFAP1 expression in a breast cancer cell line (MDA-MB-231 cells) reduced invadopodia formation (unpublished data) and invasion. 15 Although these findings highlight a relevant role for AFAP1 in modulating oncogenesis in the breast and prostate, the normal physiologic role of AFAP1 in these tissues has not been determined.
cSrc controls numerous cellular functions such as cytoskeletal remodeling, adhesion, survival and proliferation. 16 The increased activation or the overexpression of cSrc leads to dysregulation of these cellular functions and contributes to tumor progression and metastasis in human cancers including breast cancer. 17 The physiologic functions of cSrc in the breast have been studied by germline deletion [18] [19] [20] and by the conditional deletion of cSrc in mammary epithelium. 21 Notably, cSrc-null female mice experience lactation failure, 20 establishing an important physiologic role for cSrc in directing secretory activation.
Secretory activation is a series of molecular and cellular events required for the onset of copious milk production in the mammary gland at parturition. During secretory activation, the expression of specific genes that regulate milk protein and triglyceride synthesis, [22] [23] [24] as well as secretory activity within mammary epithelial cells are significantly enhanced. 22, 25 Secretory activation is regulated by prolactin, which also regulates the functional differentiation of the mammary gland during pregnancy in preparation for milk synthesis and secretion. 25, 26 cSrc is a known regulator of the prolactin signaling pathway. In response to prolactin, cSrc binds to the prolactin receptor (PrlR) 27, 28 and is required for the prolactin-induced activation of signal transducer and activator of transcription 5 (STAT5), a transcription factor downstream of PrlR-regulating milk protein expression. [29] [30] [31] cSrc can also affect the internalization of PrlR. 32 Although it is clear that prolactin serves as an input signal to activate cSrc, the exact mechanism of the activation and the regulation of cSrc activity is yet to be addressed.
Considering the prominent role of cSrc in the normal physiology of the breast and the function of AFAP1 as an adaptor and effector of cSrc, we generated a knockout (KO) mouse model of AFAP1 to determine the normal physiologic function of AFAP1 and to assess its role in lactogenesis and the postnatal development of the mammary gland. Here, we report our findings that support the hypothesis that AFAP1 has an important role in normal breast physiology and is a relevant cSrc adaptor in vivo.
RESULTS

Generation of AFAP1-null mice
To generate AFAP1 KO mice, we flanked exon 5 of the Afap1 gene with LoxP sites (a.k.a. floxed) and mated mice homozygous for the floxed gene with mice expressing Cre under the cytomegalovirus promoter to produce a heterozygote mouse containing one mutant Afap1 allele with exon 5 deleted (Afap1 +/Δexon 5 ) in every organ. These mice were intercrossed to obtain the AFAP-null mice (Afap1 Δexon 5/Δexon 5 or AFAP1 − / − ). Cre-mediated deletion of exon 5 was designed to introduce a frameshift, generating a stop codon after exon 4. A PCR genotyping strategy was designed to distinguish between the wild-type (WT), floxed and Δexon 5 allele. Figure 1a shows the location of the primers used for genotyping and the size of the corresponding PCR products in relation to the structure of the indicated alleles. A typical genotyping result is shown in Figure 1b .
AFAP1 KO mice were born at the expected Mendelian frequency from the heterozygote intercross with an equal gender ratio and were grossly normal at birth. Western blot analyses with AFAP1 antibodies confirmed the complete absence of AFAP1 protein in murine embryonic fibroblasts (MEFs, see Supplementary Materials and methods) derived from KO mice ( Figure 1c ) and in whole mammary glands (Supplementary Figure 3A ). AFAP1 protein expression was halved in AFAP1 +/ − MEFs compared with that in AFAP1 +/+ MEFs (Figure 1c ). There was no compensatory increase or decrease in the expression of AFAP1 like-2, a closely related AFAP family member, in the KO mammary gland (Supplementary Figures 3A and C). Western blotting with antibodies against the amino terminus of AFAP1 (F1, (2)) suggested that mRNA consisting of exons 1-4 was not expressed as a truncated form of AFAP1 in KO MEFs (data not shown).
Pups born to AFAP1-null dams have a poor survival Considering the role of cSrc, a known AFAP1 binding protein, in lactation, we examined KO female mice for their ability to nurse. We observed a significant decrease in the 48 h survival rate of all pups born to AFAP1 − / − and AFAP1 +/ − dams compared with that of pups born to the AFAP1 +/+ dams (Figure 2a ). The pups born to KO dams had very small or no milk spots. WT foster dams were able to nurse the pups born to KO dams, whereas KO dams could not foster pups from WT dams (data not shown). We then mated WT females with KO males and KO females with WT males and measured the average weight of all the resulting heterozygote pups daily for 2 weeks. For surviving pups born to KO mice, weight gain was significantly slower if reared by KO dams compared with that of the pups reared by WT dams (Figure 2b) . This difference in weight gain was independent of the pup genotype as all the pups were heterozygotes. These data indicated that AFAP1 − / − dams were unable to support the survival and growth of their pups owing to a deficit in their ability to lactate.
Loss of AFAP1 causes abnormality in lactating mammary glands without affecting the gross development of the mammary gland
To determine the cause of lactation failure in AFAP1 − / − mice, we assessed the postnatal development of mammary glands in these mice. Whole mounts of the 4th inguinal mammary glands were prepared at early puberty (4 weeks), sexual maturation (8 weeks), adulthood (14 weeks), late pregnancy (16.5 days postconception, P16.5; the full pregnancy is 18.5 days in C57Bl/B6) and early lactation (3 days postpartum), and analyzed microscopically. No overt differences were observed in mammary glands from virgin mice at 4, 8 and 14 weeks of age and at P16.5 ( Figure 3A (a-h)). The average length of the main ducts in the WT and the KO mammary glands at full maturation (8 weeks) was similar ( Figure 3B ). However, whole mounts of lactating mammary glands from AFAP1 − / − mice (L3) were significantly less dense with less full alveoli ( Figure 3C (k and l)) compared with those from AFAP1 +/+ mice ( Figure 3C (i and j)). We compared hematoxylin-and eosin (H&E)-stained histologic sections from mammary glands of AFAP1-WT or -null mice at different developmental stages. There were no morphologic differences between the mammary glands from WT and KO mice at 4, 8 and 14 weeks in virgin mice (data not shown) and at P16.5 ( Figure 4A ). In contrast to WT lactating mammary glands that exhibited expanded large secretory alveoli with milk residue in the lumens ( Figure 4B , left panels), KO lactating mammary glands exhibited less expanded alveoli with sparse milk residue in the lumens ( Figure 4B , right panels). Furthermore, alveolar epithelial cells from the null lactating mammary glands contained large, clear cytoplasmic droplets ( Figure 4B , right panel, arrowhead).
In alveolar epithelial cells, cytoplasmic lipid droplets (CLDs) containing milk fat increase in size and accumulate at the end of pregnancy and decrease immediately after birth as they continuously empty into the lumen with copious milk production. 20 The persistence of large CLDs postpartum is indicative of failed secretory activation. 22, 25 To confirm the identity of the enlarged droplets in KO mammary epithelial cells, we immunolabeled mammary gland histologic sections with an antibody specific for adipose differentiation-related protein that decorates the membrane of CLDs. 20, 22 The enlarged droplets within the KO lactating mammary epithelial cells were positively stained for adipose differentiation-related protein ( Figure 4C (d) , white arrow), confirming the intraepithelial retention of large CLDs. In WT epithelial cells in the lactating mammary gland, most of the CLDs aligned closely with the apical surface of the epithelial cells or fused with the plasma membrane as they emptied into the lumen ( Figure 4C (c), white arrow head). At P16.5, the size and distribution of CLDs was similar between WT and KO mammary glands ( Figure 4C (a and b) ). These data indicate a possible deficit in secretory activation in the absence of AFAP1.
To ensure that the failure in lactation did not result from a reduced number of mammary epithelial cells constituting each alveolus, which would reflect a deficit in cell proliferation during pregnancy, we counted the number of nuclei per alveolus in a captured image of a H&E section of both WT and KO lactating mammary glands. As shown in Supplementary Figure 2 , the average cell number of each KO alveolus was comparable with that of WT.
In response to prolactin, AFAP1 becomes tyrosine phosphorylated and forms a complex with cSrc Secretory activation is regulated by prolactin. To determine the response of AFAP1 to prolactin, we used the T47D mammary epithelial cell line known for its high PrlR level 17 and its requirement for cSrc in the prolactin response. 27, 33, 34 We expressed GFP-AFAP1 in T47D cells, stimulated the cells with prolactin and immunoprecipitated GFP-AFAP1. Western blotting indicated that prolactin induced the tyrosine phosphorylation of GFP-AFAP1 ( Figure 5a ) as well as endogenous AFAP1 (Figure 5b ). Furthermore, cSrc co-immunoprecipitated with endogenous AFAP1 upon stimulation of T47D cells with prolactin ( Figure 5c ). We then tested for the interaction of AFAP1 with cSrc in tissue lysates from mammary glands at P16.5 and L3. AFAP1 co-immunoprecipitated with cSrc from the mammary tissue lysates at L3 but not from those at late pregnancy ( Figure 5d ). AFAP1 was tyrosine phosphorylated in the tissue lysates from P16.5 and L3 mammary gland (Supplementary Figure 3B ). These data demonstrate that AFAP1 binds to cSrc and becomes tyrosine phosphorylated in response to prolactin stimulation.
As prolactin induces transcriptional changes in multiple genes at secretory activation, [22] [23] [24] we determined if AFAP1 expression changed. Western blot analysis on mammary gland lysates showed that the AFAP1 protein level remained constant during postnatal development, at P16.5 and at L3 (Supplementary Figure 3A) . These data indicate that prolactin does not regulate AFAP1 at the level of transcription or translation.
Loss of AFAP1 leads to reduced cSrc activation in early lactating mammary glands
Considering that AFAP1 interacts with cSrc, 8, 11, 35 we examined the effect of the loss of AFAP1 on cSrc activity in mammary glands. To measure cSrc activity, we prepared whole tissue lysates from both WT and KO mammary glands from mice at 8 weeks of age, P16.5 and L3. By western blotting, we detected active cSrc using an antibody that recognizes cSrc when it is phosphorylated on tyrosine 418 and compared it with the total level of cSrc. Phosphorylation of this tyrosine is indicative of activation, and although this antibody recognizes this phosphotyrosine in all Src family kinases, only cSrc is active during late pregnancy and early lactation. 20 In agreement with the previously published work, 20 we observed a moderate increase in cSrc activity from P16.5 to L3 in WT mammary glands ( Figure 6A ). In contrast, the level of active cSrc was markedly reduced in the AFAP1 KO mammary gland at early lactation ( Figure 6A ). Densitometry of the western blots (n = 6 for each genotype) confirmed the reduction of cSrc activity at L3 in the absence of AFAP1 ( Figure 6B ). Loss of AFAP1 did not affect the level of cSrc expression ( Figure 6C ).
Next, we visualized the location of active cSrc in the L3 mammary gland with active Src-specific antibody. In the WT mammary gland, strong staining of active cSrc was concentrated on the apical surface and the basolateral sides of luminal epithelial cells and within myoepithelial cells ( Figure 6D (a and c) , marked with asterisk, arrow and arrowhead, respectively). The level of active cSrc was generally decreased in the KO lactating mammary gland ( Figure 6D (b and d) ). Interestingly, the level of active cSrc present at the apical surface of the KO luminal epithelial cells was remarkably reduced compared with WT cells ( Figure 6D (b) , asterisk), whereas active cSrc was still detected on the basolateral sides of luminal epithelial cells ( Figure 6D (b) , arrow) and within myoepithelial cells ( Figure 6D (b) , arrowhead).There was no difference in the location or intensity of total cSrc between WT and KO lactating mammary glands and total cSrc was still present at the apical surface of lactating mammary glands of KO mice ( Figure 6E , lower panel, arrow).
We then probed for AFAP1 in histologic sections of mouse mammary glands with the F1 antibody. AFAP1 was expressed in luminal and ductal epithelial cells, as well as in myoepithelial cells (Supplementary Figure 4A (d) , arrow), which matched the AFAP1 expression pattern reported for the human mammary gland. 9 There was no increase of AFAP1 detected around the periphery of lipid droplets. We further confirmed the expression of AFAP1 in both luminal epithelial and myoepithelial cells by immunostaining primary mammary epithelial cells cultured on collagen-coated coverslips with the AFAP1 antibody. AFAP1 antibody immunostained both myoepithelial cells (positive for cytokeratin 14; Supplementary Figure 5A ) and luminal epithelial cells (positive for cytokeratin 8/18; Supplementary Figure 5B ). There was no difference in the organization of actin filaments between WT and KO mammary epithelial cells. To determine precisely the subcellular location of AFAP1, we isolated mammary luminal epithelial precursor cells and cultured them into acini in a threedimensional culture system 36 and then immunolabeled the acini with anti-AFAP1 antibody. AFAP1 was clearly visible outlining the cellular cortex with equal distribution on the basolateral and apical sides of the cells, exterior to the location of cytokeratin staining (Supplementary Figure 4B) . Therefore, the subcellular localization pattern of AFAP1 was identical to that of cSrc. Taken together, these data indicate that AFAP1 expression colocalizes with active cSrc in the lactating mammary gland, especially at the apical region of luminal epithelial cells, and is required for the normal spatial and temporal activity of cSrc associated with early lactation.
Loss of AFAP1 affects milk lipid synthesis without affecting milk protein synthesis
To identify downstream signaling pathways affected by reduced cSrc activation at secretory activation, we first examined STAT5 activation and milk protein expression. By western blotting with a phosphotyrosine-specific antibody that recognizes the active form of STAT5a and STAT5b, we observed a normal pattern of STAT5 activation in both WT and KO mammary glands including the sharp increase that normally occurs at L3 ( Figures 7A and B ). Loss of AFAP1 did not affect the level of STAT5 expression at L3 ( Figures 7A and C) . In immunolabeled histologic sections of lactating mammary glands at L3, the intensity and distribution pattern of active STAT5 ( Figure 7D (a and b) ) and total STAT5 ( Figure 7D (c and d) ) were indistinguishable between WT and null mice. Additionally, the loss of AFAP1 did not affect the expression of β-casein, which is upregulated at L3 in response to STAT5 activity 22 (Figure 7E ). These results indicate that the PlrR to STAT5 signaling axis controlling milk protein synthesis was not altered by the deletion of AFAP1.
During secretory activation and parallel to the PrlR-mediated STAT5 signaling that increases the expression of milk protein, PrlRmediated sterol regulatory element binding protein 1 (SREBP1) signaling increases the expression of genes required for lipid synthesis such as acetyl CoA carboxylase 1 (ACC1) and fatty acid synthase (FAS). 22, 24, 37 In contrast to the normal increase in the expression of SREBP1 observed in the WT L3 mammary gland during secretory activation, there was reduced expression of SREBP1 in the absence of AFAP1 ( Figure 8A, upper panel) . Moreover, the loss of AFAP1 led to the reduced expression of ACC1 and FAS ( Figure 8A ). We then assessed the lipid content of the lactating mammary gland by preparing cryosections of L3 mammary gland and staining them for lipid with Oil Red O. The KO mammary gland showed reduced lipid staining in the lumens of the alveoli and large Oil Red O-stained droplets retained within the epithelial cells ( Figure 8B ). Taken together, these results indicate AFAP1 is involved in the regulation of milk lipid synthesis, rather than milk protein synthesis, during secretory activation.
KO mammary gland shows signs of precocious involution at early lactation
In the cSrc-null lactating mammary gland, the failure of secretory activation led to precocious involution, marked by premature tyrosine phosphorylation of STAT3, 20 a hallmark of mammary gland involution. 38, 39 We observed that AFAP1 KO lactating mammary glands displayed a histologic sign of involution, the sloughing of mammary epithelial cells into the lumen that exhibited swollen cytoplasms and condensed nuclei (Supplementary Figure 6 ) even though the dams were nursing pups. 40 We then immunolabeled histologic sections of L3 mammary glands for tyrosine-phosphorylated STAT3 (active STAT3). The active STAT3 level was markedly elevated in the KO L3 mammary gland ( Figure 9A (b) ), whereas total STAT3 staining was comparable between WT and KO L3 mammary glands ( Figure 9A (c and d) ). Western blot analysis confirmed the increased activation of STAT3 in the KO lactating mammary gland ( Figure 9B) .
The nuclear translocation of CAAT enhanced binding protein delta (CEBPδ) is a downstream event of STAT3 activation and . Densitometry scans of bands representing either active pSrc (Y418) or total cSrc were quantified using ImageJ and the average ratio of pSrc (Y418) to total cSrc levels in the indicated lysates were graphed (bars = s.d., n = 6 at L3 for both WT and KO lysates). The ratio of pSrc/total Src of all the samples was normalized to that of WT at 8 weeks. The differences in active Src levels were statistically significant (Po 0.05, two-tailed t-test) for the L3 lysates. (C) An analysis similar to that described for the graph in B was used to determine the ratio of total cSrc to β-actin in lysates from mammary glands at the indicated times (bars = s.d., n = 6 at L3 for both WT and KO lysates). (D) Histologic sections of mammary glands from WT and KO mice at lactation day 3 were stained with anti-active Src (phosphoSrc(Y418)) antibody (white in a and b; yellow in c and d), cytokeratin14 (CK14, green) for myoepithelial cells, another known histologic marker of involution. 40, 41 We observed nuclear CEBPδ staining only in KO L3 mammary glands ( Figure 9C ). These data indicate that the loss of AFAP1 led to molecular and histologic signs of precocious involution in the mammary gland that accompanied failed secretory activation.
DISCUSSION
AFAP1 was originally identified in a screen for v-Src substrates. 1, 2 The structure of AFAP1 suggests that it functions as an adaptor or scaffolding protein for kinases that regulate the organization of the actin cytoskeleton. 8, 42 Although it is known that AFAP1 contributes to prostate carcinogenesis and has an important role in regulating tumorigenic potential and the adhesion of prostate and breast cancer cells, 10, 14 the normal physiologic role of AFAP1 has remained unclear. In this first study on the germline ablation of AFAP1 in mice, we have uncovered a physiologic role of AFAP1. In the normal mammary gland, AFAP1, as an adaptor of cSrc, regulates secretory activation leading to the onset of milk production.
cSrc activation is spatially coordinated. Inactive cSrc is localized to endosomes in the perinuclear region of cells and activating signals trigger the trafficking of cSrc to the plasma membrane and its concomitant activation. 43, 44 The prolactin response in the postpartum mammary gland requires cSrc activity for secretory activation and milk production. 20 In the AFAP1 KO mouse, the loss of AFAP1 in the mammary gland resulted in reduced cSrc activity and led to a failure in secretory activation and milk production. Therefore, this finding is not only consistent with the predicted role of AFAP1 as an adaptor protein of cSrc but also identifies prolactin as a novel input signal that requires the interaction between AFAP1 and cSrc for downstream signaling. Our data also suggest that the prolactin-induced binding of AFAP1 to cSrc is a required event for the specific apical positioning of active cSrc in the lactating mammary gland. Furthermore, as we did not detect an association of AFAP1 with Jak2 or PrlR or detect prolactininduced serine phosphorylation of AFAP1 by protein kinase Cα (unpublished data), we believe that the binding of cSrc to AFAP1, in contrast to other binding partners of AFAP1, is the most relevant in regulating lactation in the mammary gland.
As an adaptor of cSrc, AFAP1 would be expected to mediate only certain functions of cSrc. The germline ablation of cSrc caused delays in pubertal duct growth owing to reduced estrogen receptor α signaling. 19 In the AFAP1-null mice, the expression level and phosphorylation status of estrogen receptor α was not affected (unpublished data) and we saw no measurable delay in pubertal duct growth nor did we detect any histologic difference in the KO mammary gland during puberty and pregnancy. Therefore, AFAP1, as an adaptor of cSrc, does not regulate ductal growth under the regulation of estrogen signaling. Consistent with this, delays in pubertal ductal growth were not reported in the conditional KO of cSrc in mammary epithelial cells. 21 The increase in PrlR expression and Stat5 activation observed at the onset of lactation did not occur in the cSrc-null mouse. 20 This resulted in reduced milk protein expression. 20 Although there was a reduction of cSrc activation in AFAP1 KO lactating mammary glands, STAT5 activation and milk protein production remained intact. Therefore, AFAP1 does not participate in the PrlR to STAT5 signaling axis. Rather, our work suggests that cSrc and its interaction with AFAP1 is involved in the upregulation of key proteins in milk lipid synthesis, such as SREBP1 and its downstream targets ACC1 and FAS during secretory activation. A role for cSrc in regulating SREBP1 expression has been reported by others, 45, 46 although the precise mechanism by which it occurs has remained elusive. Our work identifies AFAP1 as a novel contributor to the regulation of the lipogenic pathway during milk production and necessitates further examination of cSrc function in lipid biosynthesis during lactation.
CLD accumulation resulting from a defect in CLD secretion can lead to failed lactation and precocious involution. 25, [47] [48] [49] Interestingly, F-actin is thought to contribute to the contractile machinery regulating CLD secretion. 50, 51 Considering that AFAP1 crosslinks F-actin in response to cSrc activation [11] [12] [13] and that F-actin participates in CLD secretion, the possibility exists that AFAP1 may act as an effector of cSrc necessary for changes in actin cytoskeletal organization during the emptying of CLDs. In addition, AFAP1 may position cSrc at the apical membrane in proximity with other effector proteins required for the emptying of CLDs into the lumen. Although our analysis of F-actin organization in isolated mammary epithelial cells in two dimensions did not show any difference between WT and KO cells, the further investigation of the role of AFAP1 and the actin cytoskeleton in the vectorial movement and the positioning of CLDs in three dimension will be required to address such possibilities.
In conclusion, our work demonstrates the requirement of an adaptor protein of cSrc, AFAP1, in specifying spatial and temporal activation of cSrc during lactation in mammary gland. AFAP1 appears to act as an effector for specific functions of cSrc, but this does not rule out functional roles for AFAP1 that are not dependent on cSrc activity. The AFAP1-null mice will allow us to uncover other physiologic and pathologic processes that are regulated by AFAP1 and those dependent on its interaction with cSrc.
MATERIALS AND METHODS
Generation and genotyping of AFAP1-null mice AFAP1 floxed mice were generated (Ozgene Pty Ltd, Gentley DC, WA, Australia), as described in the supplementary Materials and methods section. PCR genotyping was performed with the following primers: F1, 5′-AACTGGGGTGTCCTTGAGTG-3′; R1, 5′-GCACTGGGGATAAAACTTGC-3′; R3, 5′-GCAAGTCTCAACACTGCT-3′. The location of the primer and the size of the corresponding PCR products in relation to the structure of different alleles are illustrated in Figure 1a . A Blood and Tissue DNA extraction kit (Qiagen, Valencia, CA, USA) and Platinum Taq (Life Technologies, Grand Island, NY, USA) was used for DNA isolation and genotyping PCR.
Mice
All mice were maintained on a 12 h light and dark cycle at the AAALACapproved animal facility in The Commonwealth Medical College. The studies were in accordance with the Guide for the Care and Use of Laboratory Animals (NIH). Unless stated otherwise, female littermates of matching age from heterozygous intercross were used.
Survival rate and weight gain
Pup survival was calculated as the percentage of surviving pups in each litter at 48 h postpartum. Weight gain was determined for heterozygote pups born to KO female mice mated with WT males or to WT females mated with KO males. The pups were weighed daily for 2 weeks and and average pup weight was calculated by dividing the sum of the whole litter weight by the number of pups in the litter.
Whole mount preparation and histologic analysis
The carmine alum-stained whole mounts were prepared as described. 52 The fourth inguinal mammary gland were fixed in 10% neutral-buffered formalin for paraffin embedding and processed for immunohistochemistry as described. 9 Oil Red O staining of cryosections of mammary glands was performed as described. 53 Stained sections were imaged with a Axio Observer Z1 epi-fluorescence microscope (Zeiss, Oberkochen, Germany) or with a A1 confocal microscope (Nikon Instruments Inc., Melville, NY, USA).
Antibodies
Antibodies used for immunohistochemistry and western blotting were as follows: Anti-Src (GD11 from BD Bioscience, San Jose, CA, USA; 36D10 from Cell Signaling, Boston, MA, USA); anti-phosphotyrosine Src (clone 44660G from Life Technologies for immunohistochemistry; catalog no. 2101 from Cell Signaling for western blotting); anti-α-SMA (Sigma-Aldrich, St Louis, MO, USA); anti-cytokeratin 8/18 (Clone5D3; Thermo Fisher, Pittsburg, PA, USA); anti-ADFR (Abcam, Cambridge, MA, USA); wheat germ agglutinin (Life Technologies); anti-α-casein (Santa Cruz Biotech, Santa Cruz, CA, USA); anti-STAT5 and anti-phospho-STAT5 (pY694) (Cell Signaling); anti-PrlR (H-300 and G-20; Santa Cruz Biotech); anti-SREBP1 (Abcam); anti-ACC1 and anti-FAS (Cell Signaling). All fluorescence-labeled secondary antibodies were from Life Technologies. 
Morphologic analysis
To measure ductal growth, the whole mounts of mammary glands stained with Carmine alum were imaged with a Perfection photoscanner (Epson, Long Beach, CA, USA) or a M2 Bio Stereo microscope (Zeiss). The captured images were imported to Image J software (NIH Image, NIH, Bethesda, MD, USA) and analyzed as described. 54 Lines were drawn along the three longest axis of each mammary gland and the length of the nine axes was averaged.
Immunoprecipitation and western blot analysis
The T47D cell line was from ATCC (Manassas, VA, USA). GFP-AFAP1 9 or GFP alone were transfected with Fugene HD (Roche, Indianapolis, IN, USA) according to the manufacturer's protocol. The transfected cells were starved in serum-free medium for 48 h before the stimulation with ovine prolactin (100 ng/ml; Sigma-Aldrich). Lysate preparation and immunoprecipitation were preformed as described. 9 Mammary glands were pulverized in liquid nitrogen before solubilized in buffer for immunoprecipitation. 
